Adam C Palmer
University of North Carolina at Chapel Hill
H-index: 22
North America-United States
Top articles of Adam C Palmer
Ultrasensitive response explains the benefit of combination chemotherapy despite drug antagonism
Molecular Cancer Therapeutics
2024/3/26
Amy E Pomeroy
H-Index: 2
Adam C Palmer
H-Index: 16
Mechanistic models of tumor and patient heterogeneity explain and predict clinical outcomes of large B-cell lymphoma (LBCL) treatment
Cancer Research
2024/3/22
Amy E Pomeroy
H-Index: 2
Adam C Palmer
H-Index: 16
Synergistic drug combinations promote the development of resistance in acute myeloid leukemia
Blood Cancer Discovery
2024/3/1
Amy E Pomeroy
H-Index: 2
Adam C Palmer
H-Index: 16
Tumor-specific activity of precision medicines in the NCI-MATCH trial
Clinical Cancer Research
2024/2/16
Deborah Plana
H-Index: 7
Adam C Palmer
H-Index: 16
Abstract A135: Are survival benefits of new drugs in combinations due to modest benefits in most patients or large benefits in few patients?
Molecular Cancer Therapeutics
2023/12/1
Haeun Hwangbo
H-Index: 1
Adam C Palmer
H-Index: 16
Additivity predicts the efficacy of most approved combination therapies for advanced cancer
Nature Cancer
2023/12
Genetically informed therapy for lymphoma: the discomfiting benefit of lumping splits
Cancer Cell
2023/10/9
Adam C Palmer
H-Index: 16
Cell-of-origin subtypes and therapeutic benefit from polatuzumab vedotin
New England Journal of Medicine
2023/8/24
Adam C Palmer
H-Index: 16
An RNA Damage Response Network Mediates the Lethality of 5-FU in Clinically Relevant Tumor Types
bioRxiv
2023/4/29
Rationales for Combining Therapies to Treat Cancer: Independent Action, Response Correlation, and Collateral Sensitivity Versus Synergy
2023/4/11
Adam C Palmer
H-Index: 16
Cong Chen
H-Index: 7
Cancer sensitivity to therapy is constrained by apoptosis regulation in cells of origin
Cancer Research
2023/4/4
Cameron Fraser
H-Index: 5
Xingping Qin
H-Index: 8
Kenichi Shimada
H-Index: 13
Johan Spetz
H-Index: 9
Zintis Inde
H-Index: 4
Gaurav Joshi
H-Index: 1
Jennifer Guerriero
H-Index: 16
Omar Lopez
H-Index: 7
Jingwei Cheng
H-Index: 15
Charles Yoon
H-Index: 5
Kris Wood
H-Index: 21
David Kirsch
H-Index: 46
Andrew Cherniack
H-Index: 73
Anthony Letai
H-Index: 64
Additivity predicts the clinical efficacy of most approved combination therapies for advanced cancer
Cancer Research
2023/4/4
Drug independence and the curability of cancer by combination chemotherapy
2022/11/1
Amy E Pomeroy
H-Index: 2
Adam C Palmer
H-Index: 16
Predicting in vivo activity of combination therapies from in vitro drug pairs in diverse environments
Cell Reports Medicine
2022/9/20
Defining and evaluating drug additivity in clinical trials of combination cancer therapy
Cancer Research
2022/6/15
Haeun Hwangbo
H-Index: 1
Adam C Palmer
H-Index: 16
Independent drug action in combination therapy: implications for precision oncology
2022/3/1
Deborah Plana
H-Index: 7
Adam C Palmer
H-Index: 16
Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects
Nature communications
2022/2/15
Deborah Plana
H-Index: 7
Adam C Palmer
H-Index: 16
Predictable clinical benefits without evidence of synergy in trials of combination therapies with immune-checkpoint inhibitors
Clinical Cancer Research
2022/1/15
Mechanisms of antibiotic action shape the fitness landscapes of resistance mutations
Computational and Structural Biotechnology Journal
2022/1/1
Predictable clinical benefits without synergy in trials of combination therapies with immune checkpoint inhibitors
Clin. Cancer Res.
2021/3/19
Co-Authors
